NOVO NORDISK A/S PrivateDoc eagerly awaits the arrival of weight loss drug Wegovy with regulations approved as clinical trials reveals an average of 17-18% weight loss.
The drug which is manufactured by
In clinical studies where participants were required to eat healthily and exercise alongside a calorie-controlled diet, participants taking Wegovy had an average weight loss of 17-18%, approximately 34 pounds (15.3 kilograms). Participants lost weight steadily for 16 months before plateauing. In the placebo group, the average weight loss was about 2.5%.
Whilst there are currently weight loss injections available for private prescriptions such as Saxenda; what is particularly exciting about Wegovy is that the injectable only needs to be taken weekly.
Wegovy is administered with a single injection once per week, under the skin. As with all prescribed weight loss drugs it will be prescribed only to qualifying patients and is to be combined with healthy eating and exercise. Despite safety concerns, the treatment can be safely prescribed by a GP with experience in weight loss treatment.
With Obesity levels in the
"Despite the best efforts to lose weight, many people with obesity struggle to achieve and maintain weight loss due to physiological responses that favour weight regain," said
Decreasing your weight when faced with an obese BMI ( 30 or more) brings a plethora of health benefits such as improved energy, sleep, better blood pressure, blood sugar and cholesterol levels, less risk of further health complications and a better relationship with body image and diet.
Wegovy joins a range of effective weight-loss drugs such as Saxenda and Mysimba, that have been proven to help tackle rising obesity. We anticipate the arrival of Wegovy in the
.
(C) 2021 M2 COMMUNICATIONS, source
